J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
David M. O'Malley,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert G. Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,Elizabeth M. Swisher,Lara Maloney,Sandra Goble,Kevin K. Lin,Tanya Todorova Kwan,Jonathan A. Ledermann,Robert E. Coleman +21 more
TL;DR: The ARIEL3 trial as mentioned in this paper showed that rucaparib treatment was associated with exceptional benefit compared with placebo: 79/375 (21.1%) vs 4/189 (2.1%), respectively (p < 0.0001).
Journal ArticleDOI
Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.
Eric Pujade-Lourraine,Nicoletta Colombo,Mary L. Disis,Keiichi Fujiwara,Jonathan A. Ledermann,Mansoor Raza Mirza,Gary Richardson,J. Thaddeus Beck,Stephanie Gaillard,Patricia Haney,Michael Shnaidman,Alexei Morozov,Bradley J. Monk +12 more
TL;DR: This open-label, multicenter, 3-arm, phase 3 trial compares avelumab ± pegylated liposomal doxorubicin (PLD) vs PLD alone in pts with platinum-resistant/refractory ovarian cancer, and is the first phase3 trial of a checkpoint inhibitor in ovarian cancer.
Journal ArticleDOI
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Sophie E. Willis,Claudia Winkler,Martine P. Roudier,Tarrion Baird,Paola Marco-Casanova,Emma V. Jones,Philip Rowe,Jaime Rodriguez-Canales,Helen K. Angell,Felicia S.L. Ng,Paul M Waring,Darren Hodgson,Jonathan A. Ledermann,Johanne I Weberpals,Emma Dean,Elizabeth A. Harrington,J. Carl Barrett,Andrew J. Pierce,Elisabetta Leo,Gemma N Jones +19 more
TL;DR: In this paper, the authors developed and validated a clinically applicable SLFN11 immunohistochemistry assay and retrospectively correlated SLFN 11 tumour levels to patient outcome to the standard of care therapies and olaparib maintenance.
Journal ArticleDOI
STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.
Tim Mould,Alison Brand,Hans W. Nijman,Jonathan A. Ledermann,Richard J. Edmondson,Jeremy Twigg,Emma Hudson,Carien L. Creutzberg,Naveena Singh,Raji Ganesan,Amanda Feeney,Laura Farrelly,Laura Hughes,Allan Hackshaw,Abigail Sharp,Peey-Sei Kok,Henry C Kitchener +16 more
TL;DR: The benefit of lymphadenectomy on survival in stage 1 endometrial cancer remains uncertain and the use of nodal status after lymph no...
Proceedings ArticleDOI
Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma
David M. O'Malley,Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Iain A. McNeish,Elizabeth M. Swisher,Clare L. Scott,Gottfried E. Konecny,Heidi Giordano,Terri Cameron,Lara Maloney,Sandra Goble,James Sun,Thomas Harding,Kevin K. Lin,Jonathan A. Ledermann +19 more
TL;DR: Next-generation sequencing on carcinomas from a double-blind, placebo-controlled, phase 3 study of rucaparib in patients with HGOC following response to platinum-based chemotherapy found high genomic loss of heterozygosity, which is a type of genomic scar characteristic of HRR deficiency.